ValeurQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMFrais de vente, généraux et administratifs2.86 B2.55 B2.65 B2.63 B2.9 B2.7 B10.88 BRecherche et développement4.58 B3.62 B4.05 B4.23 B3.89 B12.59 B24.76 BRésultat d'exploitation1.64 B5.87 B4.99 B6.51 B375 M-3.4 B8.48 BTotal des produits hors exploitation123 M202 M150 M430 M-298 M-7 M275 MCharges d'intérêts, nettes des intérêts capitalisés328 M313 M305 M327 M412 M479 M1.52 BRésultat hors exploitation, hors charges d'intérêts-76 M-146 M-162 M-135 M-279 M-348 M-924 MRevenus/dépenses exceptionnels-129 M35 M7 M238 M-431 M-138 M-324 MRésultat avant impôts4.17 B5.9 B5 B6.75 B3.42 B-3.53 B11.63 BPart des actionnaires dans le résultat———————Impôts426 M818 M571 M958 M457 M709 M2.69 BIntérêts ne donnant pas le contrôle / intérêts minoritaires1 M6 M1 M2 M0-3 M0Autres produits/charges après impôts101 M-109 M-335 M51 M-118 M-20 M-422 MRésultat net avant activités abandonnées3.74 B5.08 B4.43 B5.79 B2.96 B-4.24 B8.94 BActivités abandonnées———————Résultat net3.74 B5.08 B4.43 B5.79 B2.96 B-4.24 B8.94 BAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires3.74 B5.08 B4.43 B5.79 B2.96 B-4.24 B8.94 BBénéfice par action de base (BPA de base)1.482.011.762.321.21-1.723.57Bénéfice par action dilué (BPA dilué)1.492.011.762.321.19-1.723.55Nombre moyen d'actions de base en circulation2.53 B2.52 B2.51 B2.5 B2.5 B2.47 B—Nombre d'actions en circulation après dilution2.54 B2.53 B2.51 B2.5 B2.51 B2.47 B—EBITDA2.84 B6.97 B6.11 B7.66 B2.84 B-1.88 B14.73 BEBIT1.64 B5.87 B4.99 B6.51 B375 M-3.4 B8.48 BCoût des ventes3.83 B3.42 B3.56 B3.85 B5.55 B4.2 B17.16 BAutres coûts des ventes———————Amortissements (flux de trésorerie)1.2 B1.1 B1.12 B1.15 B2.47 B1.51 B6.25 B
Merck & Company, Inc. Common Stock
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue.
The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products.
The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000.
In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck".